Arrivo BioVentures Starts Ph 1 Of SP-624 For Women`s Major Depression
10 Oct 2024 //
BUSINESSWIRE
Arrivo`s RABI-767 For Acute Pancreatitis Receives FDA Fast Track Status
15 Jul 2024 //
BUSINESSWIRE
Arrivo Bio Initiates Large Phase 2b Trial For MDD SIRT6 Activator
16 Apr 2024 //
BUSINESSWIRE
Arrivo bags $45M Series B to fund major depression late-stage test
29 Nov 2023 //
ENDPTS
Arrivo`s depression med flunks ph. 2, shows benefit for women
17 Oct 2022 //
FIERCEBIOTECH